J. Wallmark

Pembrolizumab for the Treatment of Advanced Salivary Gland Carcinoma

J. Gilbert, D. Day, S. Piha-Paul, 2018, American journal of clinical oncology.

Tamoxifen's impact on the management of breast cancer: the oncologist's perspective.

J. Glick, V. Avilés, J. Wallmark, 1997, Oncology.

Preliminary results for the advanced salivary gland carcinoma cohort of the phase 1b KEYNOTE-028 study of pembrolizumab.

J. Gilbert, D. Day, S. Piha-Paul, 2016 .

Preference for the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer (PHranceSCa): A randomised, open-label phase II study.

M. Burotto, L. Fallowfield, S. Margolin, 2021, European journal of cancer.

Pembrolizumab for patients with advanced prostate adenocarcinoma: Preliminary results from the KEYNOTE-028 study

P. Ott, Juanita Lopez, S. Piha-Paul, 2016 .

Pembrolizumab for advanced prostate adenocarcinoma: findings of the KEYNOTE-028 study

P. Ott, Juanita Lopez, S. Piha-Paul, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Safety and antitumor activity of the anti–PD-1 antibody pembrolizumab in patients with advanced colorectal carcinoma

A. Santoro, S. Piha-Paul, R. Cohen, 2017, PloS one.

Phase Ib Study of Drozitumab Combined With First-Line mFOLFOX6 Plus Bevacizumab in Patients with Metastatic Colorectal Cancer

L. Amler, H. Stern, J. Baranda, 2012, Cancer investigation.

A phase II/III randomized trial of two doses of MK-3475 versus docetaxel in previously treated subjects with non-small cell lung cancer.

R. Herbst, S. Ramalingam, P. Baas, 2014 .

502 Pembrolizumab (MK-3475) for patients (pts) with advanced colorectal carcinoma (CRC): Preliminary results from KEYNOTE-028

A. Santoro, L. Siu, S. Piha-Paul, 2015 .